Replies to post #262908 on Amarin Corp Plc (AMRN)

[bfost]

Could you see a Cardiologist actually prescribing an unapproved Generic for a Heart Condition? I would think they would want to stay so far away from something like that..

Johnking - it doesn't matter what the doctor prescribes. What matters is what the insurers formulary GIVES to the patient. If the formulary software says generic V is on the formulary then generic V is given - regardless that the doc wrote for brand Vascepa.

[jessellivermore]

john....

I do not see that happening..but as i have posted...Brand Vascpa in this case will have lower Tier than Generic Vascepa because G. Vascepa will only be approved for high trigs...and even if the the plan is to off label gen Vascepa...The court decision is that gen V can not be prescribed for CVD events...So it can only be sold for the Marine indication regardless if it is used off label...

That means Gen Vascepa must face competition with drugs like Lovaza, G, Lovaza, Niacin, fibrates and all of these are cheaper than G.Vascep..So the generic company has the same problem Vascepa had last year which is a high Tier meaning the scripts will have to compete with cheaper alternatives..Which means Gen Vascepa will be Tier 4...

The paradox here is the brand will be cheaper than the Generic because there are no cheper alternatives for the CVD event label..

":>) JL